
Sign up to save your podcasts
Or


Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.
By The Uromigos4.9
5757 ratings
Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

21,950 Listeners

32,252 Listeners

30,719 Listeners

502 Listeners

1,305 Listeners

16 Listeners

59 Listeners

8,791 Listeners

23 Listeners

2 Listeners

61 Listeners

2,050 Listeners

2,146 Listeners

197 Listeners

46 Listeners